CNTA - Company ID 0001847903
Centessa Pharmaceuticals plc trades as CNTA and has a market capitalization of $6.27 B, making it the #1250 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $15.00M and net income of -$197.53M. This page tracks Centessa Pharmaceuticals plc through 576 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-07-09
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Major company event | 8-K | 2026-05-22 |
| Insider trade | 4 | 2026-05-18 |
| SCHEDULE 13G | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-13 |
| DEFM14A | - | 2026-05-07 |
| SCHEDULE 13G/A | - | 2026-05-06 |
| Quarterly report | 10-Q | 2026-05-05 |
Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders – Centessa Pharmaceuticals
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences – Centessa Pharmaceuticals
Centessa Pharmaceuticals Announces Poster Presentation of New Preclinical Data Supporting Expansion of Orexin Receptor 2 (OX2R) Agonist Pipeline into Neuropsychiatric Indications at the 64th ACNP Annual Meeting – Centessa Pharmaceuticals
The largest companies sharing Centessa Pharmaceuticals plc's SEC industry classification (pharmaceutical preparations).
Centessa Pharmaceuticals plc (CNTA) has a market capitalization of $6.27 B as of 2026-07-09, ranking #1250 among US-listed companies.
Centessa Pharmaceuticals plc reported revenue of $15.00M for fiscal year 2025.
In its latest fiscal year Centessa Pharmaceuticals plc reported a net loss of $197.53M.